Porrata L F, Litzow M R, Tefferi A, Letendre L, Kumar S, Geyer S M, Markovic S N
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Leukemia. 2002 Jul;16(7):1311-8. doi: 10.1038/sj.leu.2402503.
Absolute lymphocyte count (ALC) recovery correlates with survival after autologous hematopoietic stem cell transplantation (AHSCT) for patients with multiple myeloma, non-Hodgkin's lymphoma, and metastatic breast cancer. The role of ALC recovery in relationship to clinical outcome after AHSCT in patients with acute myelogenous leukemia is unknown. We analyzed 45 patients who underwent AHSCT at Mayo Clinic, Rochester, Minnesota between 1990 and 2000. The ALC threshold was selected at 500 cells/microl on day 15 post-AHSCT based on our previous studies. Thirty-two females and 13 males were included in the study with a median age of 45 years (range 12-75). The median follow-up was 14 months with a maximum of 129 months. The median overall and leukemia-free survival were significantly better for the 23 patients with ALC at day 15 > or =500 cells/microl compared with 22 patients with ALC <500 cells/microl (not yet reached vs 10 months, P < 0.0009; 105 vs 9 months, P < 0.0008, respectively). In conclusion, ALC > or =500 cells/microl on day 15 post-AHSCT is associated with better survival in acute myelogenous leukemia and requires further studies.
对于多发性骨髓瘤、非霍奇金淋巴瘤和转移性乳腺癌患者，绝对淋巴细胞计数（ALC）恢复情况与自体造血干细胞移植（AHSCT）后的生存率相关。急性髓性白血病患者AHSCT后ALC恢复与临床结局之间的关系尚不清楚。我们分析了1990年至2000年间在明尼苏达州罗切斯特市梅奥诊所接受AHSCT的45例患者。根据我们之前的研究，将AHSCT后第15天的ALC阈值设定为500个细胞/微升。该研究纳入了32名女性和13名男性，中位年龄为45岁（范围12 - 75岁）。中位随访时间为14个月，最长为129个月。与AHSCT后第15天ALC<500个细胞/微升的22例患者相比，ALC≥500个细胞/微升的23例患者的中位总生存期和无白血病生存期显著更长（分别为未达到与10个月，P<0.0009；105个月与9个月，P<0.0008）。总之，AHSCT后第15天ALC≥500个细胞/微升与急性髓性白血病患者更好的生存率相关，需要进一步研究。
